menu
    • menu
    [{"orgOrder":0,"company":"Sanzyme","sponsor":"J.B.Chemicals & Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Lacticacid Bacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals"},{"orgOrder":0,"company":"Sanzyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic Strain SNZ 1969","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanzyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sanzyme

    Menu

    Sanzyme

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanzyme

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Sanzyme

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic Strain SNZ 1969

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotic Strain SNZ 1969® Helps Manage IBS-D & IBS-C Symptoms Effectively, Latest Clinical Study Shows

                            Details : Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing IBS...

                            Product Name : SNZ 1969

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            November 29, 2022

                            Lead Product(s) : Probiotic Strain SNZ 1969

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanzyme

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Sanzyme

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacticacid Bacillus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : J.B.Chemicals & Pharmaceuticals

                            Deal Size : $84.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            JB Chemicals To Acquire Brands from Sanzyme For Rs, 628 Crore

                            Details : The probiotic portfolio includes Sporlac, which is the third-largest probiotics brand in India, and specialised products like Lobun used for delaying progression of chronic kidney disease and Oxalo, an alternate risk-free therapy to decalcify kidney ston...

                            Product Name : Sporlac

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : Lacticacid Bacillus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : J.B.Chemicals & Pharmaceuticals

                            Deal Size : $84.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth